Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window For children ...

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial treatment option for drug-resistant urinary tract infections (UTIs). In clinical trials, ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved gepotidacin (Blujepa, GSK), a new oral antibiotic for uncomplicated urinary tract infections (UTIs) in females aged 12 years ...

Earlier research raised concerns about antibiotic use during the first trimester of pregnancy and risk for congenital malformations. In this study, the risk of malformation was higher for infants ...

Fosfomycin is effective against Gram-positive and Gram-negative bacteria, including drug-resistant strains, and is economically viable for treating uncomplicated UTIs. A meta-analysis of 22 studies ...

Bacteria cause urinary tract infections (UTIs), so antibiotics are the first-line treatment. Even when symptoms disappear, a person should finish their antibiotic course according to their doctor’s ...

First-line antibiotics for uncomplicated urinary tract infection (UTI) remain more effective than fluoroquinolones and beta-lactams, with a 1.78% lower risk for 30-day revisits than fluoroquinolones ...

GSK may have pushed back plans to secure approval for gepotidacin as the first new urinary tract infection (UTI) treatment in 20 years, but fresh phase 3 results have lined up the antibiotic for a ...

After menopause, decreased estrogen can alter the urinary tract, making it more prone to infections. A recurrent UTI is typically defined as two or more infections within 6 months, or three or more in ...

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial treatment option for drug-resistant urinary tract infections (UTIs). In clinical trials, ...